NIH-funded study shows sorafenib improves progression-free survival for patients with rare sarcomas

see url Interim results from a clinical trial for patients with desmoid tumors or aggressive fibromatosis (DT/DF) show that the drug sorafenib tosylate (Nexavar) extended progression-free survival compared with a placebo.

see url …read more

follow Source:: Cancer

http://broadwaybathrooms.com/?deribene=binary-options-demo-practice-account&984=c4